Abstract
We report the case of a patient with systemic juvenile idiopathic arthritis (s-JIA) receiving tocilizumab (TCZ) who experienced relapses of s-JIA after receiving influenza vaccination. Systemic symptoms of s-JIA might be masked during TCZ therapy. Careful observation with the monitoring of serum interleukin (IL)-18 and IL-6 levels may be useful.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Arthritis, Juvenile* / drug therapy
-
Child, Preschool
-
Drug Interactions
-
Female
-
Humans
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects*
-
Interleukin-18 / blood
-
Interleukin-6 / blood
-
Recurrence
-
Vaccination
Substances
-
Antibodies, Monoclonal, Humanized
-
Influenza Vaccines
-
Interleukin-18
-
Interleukin-6
-
tocilizumab
Supplementary concepts
-
Rheumatoid Arthritis, Systemic Juvenile